HD-OPM Archive
Topics › Insulin resistance & diabetes

Gerald Shulman honored for showing how ectopic fat causes insulin resistance

Louis Nervegna · Aug 03, 2025 · ♥ 4 reactions · 3 comments · original Facebook post
Insulin resistance & diabetesWeight, visceral & liver fat
AI summary & key facts

Louis highlights Yale's Gerald Shulman, recognised for discovering molecular mechanisms by which fat in liver and muscle directly causes insulin resistance, including in lean people.

Gerald Shulman is recognized for discovering the molecular mechanisms by which ectopic fat accumulation in the liver and muscle directly cause insulin resistance.

His work has revolutionized the biological understanding of what causes diabetes.

(It explains why fat accumulation in liver and muscle causes insulin resistance even in lean individuals.)

From the Yale School of Medicine

Quoted:

“Gerald I. Shulman, MD, PhD, George R. Cowgill Professor of Medicine (Endocrinology) and professor of cellular and molecular physiology, and co-director of the Yale Diabetes Research Center, received the 2023 European Association for the Study of Diabetes (EASD)-Lilly Centennial Anniversary Prize. The award recognizes individual researchers who have made landmark achievements in the pathogenesis of diabetes.”

“As part of his award, Shulman will give a lecture titled “The Role of Ectopic Lipid in Insulin Resistance and Cardiometabolic Disease” at the EASD annual meeting, in Hamburg, Germany, on October 6, 2023.

Over the past three decades, Shulman has been studying the molecular basis for insulin resistance.”

Quoted:

“This mechanism by which ectopic lipid in liver and muscle promotes insulin resistance explains why even lean individuals can be susceptible to insulin resistance and cardiometamolic disease and how weight loss and agents that promote weight loss, such as the new class of GLP-1 agonists, reverse insulin resistance and type 2 diabetes,” Shulman said.

Shulman’s work has led to several paradigm shifts in the understanding of type 2 diabetes, as well as the development of new therapeutics that reduce excess ectopic lipid in the liver and muscle by promoting increase fat oxidation in these organs.

“Given our new understanding of the molecular basis of insulin resistance and the new drugs in development to target this mechanism, I’m very optimistic about the future of treating insulin resistance and cardiometabolic disease to promote metabolic health,” Shulman said.

#geraldshulmanHD #yaleHD #insulinresistanceHD #liverfatHD #musclefatHD #weightlossHD #diabetesHD #roytaylorHD #liverfatsummaryHD

medicine.yale.eduShulman Awarded EASD-Lilly Centennial Anniversary PrizeGerald I. Shulman, MD, PhD, George R. Cowgill Professor of Medicine (Endocrinology) and professor of cellular and molecular physiology, received the 2023medicine.yale.edu

Research cited

← newer: Even 1.85-3% liver fat, below the fatty liver threshold, is older: Yale: type 2 diabetes can be reversed, according to Gerald S →